Company Filing History:
Years Active: 2006-2013
Title: Masayuki Towatari: Innovator in Antitumor Drug Screening
Introduction
Masayuki Towatari is a prominent inventor based in Aichi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of methods for screening candidate compounds for antitumor drugs. With a total of 3 patents to his name, Towatari's work has the potential to impact cancer treatment significantly.
Latest Patents
Towatari's latest patents focus on a method for screening candidate compounds for antitumor drugs. His investigations into the frequency of FLT3/ITD found in various blood cancers have revealed a notably high frequency in acute myeloblastic leukemia. Studies conducted on the effects of FLT3/ITD in blood cell lines have shown that the tyrosine residues in FLT3/ITD are constitutively phosphorylated. Furthermore, blood cells that have FLT3/ITD introduced exhibit IL-3 independent proliferation. These cells are also capable of forming tumors and inhibiting cell differentiation. Towatari and his team have discovered that it is possible to screen for pharmaceutical compounds against tumors by using the inhibition of these FLT3/ITD functions as an index.
Career Highlights
Masayuki Towatari is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at Chugai has allowed him to focus on innovative research that aims to improve cancer treatment options.
Collaborations
Towatari has collaborated with notable colleagues, including Hitoshi Kiyoi and Tomoki Naoe. Their combined expertise has contributed to the advancement of research in the field of antitumor drug development.
Conclusion
Masayuki Towatari's innovative work in screening candidate compounds for antitumor drugs showcases his dedication to improving cancer treatment. His contributions, along with his collaborations, highlight the importance of research in the fight against cancer.